Drug
Afimetoran
Afimetoran: highest development phase Phase 2/3, developed by Beeline Medicines Corporation. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Beeline Medicines Corporation
Trials
| Drug | Phase | Indication |
|---|---|---|
| Afimetoran NCT07881120 | Phase 2/3 | Cutaneous Lupus Erythematosus (CLE) |
Latest
No recent events.
Follow Afimetoran on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.